BrightPath Biotherapeutics Co., Ltd.

BrightPath Biotherapeutics develops novel immunotherapies against cancer using proprietary platforms such as iPSC-derived natural killer T-cell therapies. The company has demonstrated initial safety and early activity in a first-in-human trial of unmodified iPS-NKT cells for head and neck cancer. Its pipeline includes peptide vaccines, gene-modified cell therapies like HER2-targeted CAR-iNKT/CAR-T products now entering or preparing for early-phase trials, as well as antibody-based immunomodulators. Early results show promise in tumor control with durable responses in preclinical models; clinical data are emerging from ongoing investigator-led studies at leading Japanese institutions.[1][7]